Merck (MRK) Total Current Liabilities (2009 - 2026)
Merck (MRK) posted quarterly Total Current Liabilities of $26.9 billion for Q1 2026, up 7.04% year-over-year from $25.2 billion in Q1 2025, and down 4.88% quarter-over-quarter from $28.3 billion in Q4 2025.
Merck (MRK) Total Current Liabilities (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Total Current Liabilities for 18 consecutive years, with $26.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 7.04% year-over-year to $26.9 billion; the TTM figure through Mar 2026 stood at $26.9 billion (up 7.04% YoY), while the FY2025 annual figure was $28.3 billion, changed 0.33% from the prior year.
- Total Current Liabilities slipped to $26.9 billion in Q1 2026 per MRK's latest filing, from $28.3 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $29.6 billion in Q3 2024 and bottomed at $22.3 billion in Q1 2022.
- Historically, Total Current Liabilities has averaged $25.4 billion across 5 years, with a median of $25.2 billion in 2025.
- Annual changes were most pronounced in 2022 — Total Current Liabilities slipped 15.34% — and 2024, when it grew 28.11%.
- Merck's Total Current Liabilities stood at $24.2 billion in 2022, then climbed by 6.0% to $25.7 billion in 2023, then gained by 10.61% to $28.4 billion in 2024, then slipped by 0.33% to $28.3 billion in 2025, then dropped by 4.88% to $26.9 billion in 2026.
- Business Quant data shows MRK's Total Current Liabilities at $26.9 billion in Q1 2026, $28.3 billion in Q4 2025, and $28.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.69 Bn | 631.94 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 469.96 Bn | 463.39 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 375.18 Bn | 368.04 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 303.14 Bn | 295.45 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 257.49 Bn | 252.59 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 236.49 Bn | 222.50 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 182.35 Bn | 179.17 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Sanofi | 55.15 Bn | 47.77 Bn | 10.79 Bn | 37.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.73 Bn |
| Mar 31, 2026 | 26.95 Bn |
| Dec 31, 2025 | 28.33 Bn |
| Sep 30, 2025 | 28.63 Bn |
| Jun 30, 2025 | 26.04 Bn |
| Mar 31, 2025 | 25.17 Bn |
| Dec 31, 2024 | 28.42 Bn |
| Sep 30, 2024 | 29.59 Bn |
| Jun 30, 2024 | 26.06 Bn |
| Mar 31, 2024 | 25.10 Bn |
| Dec 31, 2023 | 25.69 Bn |
| Sep 30, 2023 | 23.09 Bn |
| Jun 30, 2023 | 23.39 Bn |
| Mar 31, 2023 | 23.13 Bn |
| Dec 31, 2022 | 24.24 Bn |
| Sep 30, 2022 | 23.00 Bn |
| Jun 30, 2022 | 23.17 Bn |
| Mar 31, 2022 | 22.32 Bn |
| Dec 31, 2021 | 23.87 Bn |
| Sep 30, 2021 | 23.73 Bn |